CGF – UBS rates the stock as Buy

By Broker News | More Articles by Broker News

The company has acquired Dexion Capital, an alternative investments group based in London. UBS believes this is a logical extension of the Fidante business but does not materially move the dial.

The broker estimates Dexion will add around 15% to funds management earnings and is 1.5% accretive to earnings on a full-year basis.

The broker retains a Buy rating and $7.80 target.

Sector: Diversified Financials.

Target price is $7.80.Current Price is $6.82. Difference: $0.98 – (brackets indicate current price is over target). If CGF meets the UBS target it will return approximately 13% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →